[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:sf3b1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"SF3B1 Gene",10,8,[8,16,23,29,35,41,47,54,60,67],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05641831","Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study",[12],"Phase 2","RECRUITING","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.648361Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06313437","Revumenib in Combination With 7+3 + Midostaurin in AML",[20],"Phase 1","2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.835411Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04659616","Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",[20],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.717298Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06152809","CIML NK Cells With Venetoclax for AML",[20],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06366789","Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.326010Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[12],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.732946Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT03013998","Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",[51],"Phase 1\u002FPhase 2","2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.183972Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04588922","Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML",[51],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:28.806272Z",{"nct_id":61,"title":62,"phases":63,"status":64,"updated_at":65,"content_modified":66},"NCT07549451","Phase 2 Study Of Imetelstat for Patient With Myelodysplastic\u002FMyeloproliferative Neoplasms",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:17.877565Z","2026-05-05T02:43:27.307443Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT05732961","Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS\u002FMPN Neoplasms",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:59:02.155507Z","2026-05-05T02:43:28.651417Z"]